EUVIMEDEUVIMED entdecken
Open Access

Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis

Anna Homeniuk, Gokul Karthikeyan, Anas Atrash

Cureus · 02.06.2026

DOI: 10.7759/cureus.110145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 02.06.2026. Verfasst von Anna Homeniuk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

alkylating agentsmantle cell lymphoma (mcl)primary burkitt lymphomapropensity score matching (psm)real-world datatumor lysis syndrome

Autor:innen und Institutionen

  • Internal Medicine, University of Pittsburgh Medical Center, Harrisburg, USA.
  • College of Medicine, Drexel University, Philadelphia, USA.

Zitieren

APA

Homeniuk, A., Karthikeyan, G., & Atrash, A. (2026). Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis. Cureus. https://doi.org/10.7759/cureus.110145

Vancouver

Homeniuk A, Karthikeyan G, Atrash A. Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis. Cureus. 2026. doi:10.7759/cureus.110145

BibTeX
@article{Homeniuk2026,
  author = {Homeniuk, Anna and Karthikeyan, Gokul and Atrash, Anas},
  title = {Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.110145}
}
Kostenlos starten →